General Information of Drug (ID: DMNTCV4)

Drug Name
MBX-8025 Drug Info
Synonyms
Ppar; A agonist 2; SCHEMBL4950228; CHEMBL3545019; XJHXZGHPCAKRFK-UHFFFAOYSA-N; HY-100120; CS-0018099; {2-Methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2/3 [1]
Familial hypercholesterolemia 5C80.00 Phase 2 [2]
Primary biliary cholangitis DB96.1 Phase 2 [3]
Cross-matching ID
PubChem CID
11236126
CAS Number
CAS 851528-79-5
TTD Drug ID
DMNTCV4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [5]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [6]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [7]
KD3010 DMNFDYE Metabolic disorder 5C50-5D2Z Phase 1 [8]
SAR351034 DM15PG9 Dyslipidemia 5C80-5C81 Phase 1 [9]
CER-002 DMLBKZV Dyslipidemia 5C80-5C81 Phase 1 [10]
PMID25416646-Compound-Figure5-C DM17FKL N. A. N. A. Patented [11]
GW-501516 DMPL2KM Type-1 diabetes 5A10 Discontinued in Phase 4 [12]
Sodelglitazar DMJ816F Hyperlipidaemia 5C80 Discontinued in Phase 2 [13]
Indeglitazar DMS56UD Type-2 diabetes 5A11 Discontinued in Phase 2 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor delta (PPARD) TT2JWF6 PPARD_HUMAN Agonist [4]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024671)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
5 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
6 Phrma report (2013 Alzheimers disease)
7 T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
8 Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
9 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
10 Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
11 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
12 Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
13 Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
14 Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.